Finely tuned large language models can extract PD-L1 biomarker details from electronic health records
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...
Fierce Pharma2d
AstraZeneca touts disease recurrence win, ‘strong trend’ in survival benefit for Imfinzi in early stomach cancer
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
BioSpace2d
AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
Targeted Oncology1d
Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment
Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, ...
MedPage Today on MSN3d
AI and Mammography; Breast Cancer and Sexual Well-Being; Malaria Drug for Cancer?
Breast cancer patients who underwent postmastectomy breast reconstruction had lower sexual well-being scores compared with ...
Business Wire3d
PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies Market Research 2025: Ivonescimab has Set the Bar for Competitors - Business, Pipeline and Competitor Analysis ...
DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ...
Managed Healthcare Executive4d
Study Explores Immunotherapy vs. Chemoimmunotherapy Decisions For Advanced Non-Small Lung Cancer
The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...
MPR2d
Tevimbra Plus Chemotherapy Approved as First-Line Tx for Advanced Esophageal Cancer
The Food and Drug Administration (FDA) has approved Tevimbra® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the ...